Al-Ola Abdallah, MD, University of Kansas Medical Center, Westwood, KS, shares insights into the efficacy and role of iberdomide in relapsed/refractory (R/R) multiple myeloma. Dr Abdallah anticipates that future efforts will look at combining iberdomide with other agents to increase response rates (R/R) but notes that direct comparison in randomized trials is required to confirm whether cereblon E3 ligase modulators (CELMoDs) are more effective and less toxic than other immunomodulatory drugs. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
